Yiliang Zhang1,
Xiaofan You1,
Yuyan Ren2,
Jinpeng Cui1 
1Department of Clinical Laboratory, Yantai City Yantaishan Hospital, No. 10087, Keji Avenue, Laishan District, Yantai City, Shandong Province, China;
2Outpatient Department, Yantai City Yantaishan Hospital, No. 10087, Keji Avenue, Laishan District, Yantai City, Shandong Province, China.
For correspondence:- Jinpeng Cui
Email: pajingtong2572@126.com
Accepted: 31 January 2023
Published: 28 February 2023
Citation:
Zhang Y, You X, Ren Y, Cui J.
Implications of statin metabolism-related gene testing in guiding individualized drug use in cardiovascular diseases. Trop J Pharm Res 2023; 22(2):447-452
doi:
10.4314/tjpr.v22i2.30
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract
Purpose: To determine the value of statin metabolism-related gene testing in guiding individualized drug use in cardiovascular and cerebrovascular diseases.
Methodology: A total of 158 eligible patients with cardiovascular and cerebrovascular diseases in the Outpatient Department, Yantai City Yantaishan Hospital, Laishan District, Shandong Province were recruited and assigned based on their diseases to group A (81 patients with coronary heart disease), group B (77 patients with cerebral infarction). The control group comprised 75 healthy individuals.
Results: The GG, GT, and TT genotypes in ABCB1 (2677G > T) in group A had a G allele frequency of 0.556 and a T allele frequency of 0.444, while CC, CT, and TT genotypes in ABCB1 (3435C > T) in group A had a C allele frequency of 0.555 and a T allele frequency of 0.445. Significant differences were observed in the effectiveness of statins in treating patients with different genotypes (p < 0.05).
Conclusion: Genetic testing related to statin metabolism is of significant value in guiding the use of medication in patients with cardiovascular disease, as most of these patients present with dyslipidaemia. Significant individual differences in gene polymorphisms exist between patients with the same disease.
Keywords: Statins, Metabolism-related gene testing, Cardiovascular diseases, Individualized medication guidance, Value analysis
Fulltext in PDF
